Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance, with robust growth in key sectors and optimistic guidance. New program ramps and emerging market momentum in Aerospace and Defense, alongside automation and AI initiatives, enhance operational efficiency. Despite some uncertainties in component lead times and vague management responses, the overall sentiment is positive, supported by a high ROIC and effective cash cycle management. Given the market cap, the stock is expected to react positively, likely in the 2% to 8% range.
Revenue Revenue of $1.07 billion met the midpoint of guidance range, representing a robust 10% increase year-over-year. The increase was driven by significant expansion in Healthcare/Life Sciences and Aerospace and Defense market sectors, associated with multiple program ramps and stronger-than-anticipated demand from semicap and energy.
Non-GAAP EPS Non-GAAP EPS of $1.78 met the high end of guidance range, reflecting very strong operating performance despite significant near-term investments in additional capacity, program ramps, and technology.
Aerospace and Defense Revenue Revenue increased 3% sequentially in the fiscal first quarter, slightly below expectation due to customer end-of-year inventory management. Fiscal 2026 revenue growth for this sector is expected to exceed the 9% to 12% goal, supported by new program ramps, strong defense subsector growth, and modest growth in commercial aerospace subsector.
Healthcare/Life Sciences Revenue Revenue increased 10% sequentially, aligned with expectations of a high single to low double-digit increase. Fiscal 2026 revenue growth for this sector is anticipated to exceed the 9% to 12% goal, supported by ongoing and new program ramps and improved end market demand across therapeutics and monitoring subsectors.
Industrial Sector Revenue Revenue declined 8% sequentially, in line with forecast. Fiscal 2026 revenue growth for this sector is expected to approach the 9% to 12% growth goal, supported by new program ramps and robust growth in semicap subsector, offsetting demand softness in other subsectors.
Gross Margin Gross margin of 9.9% was consistent with guidance and the last quarter, despite a slight margin impact from the opening of a new Malaysia facility.
Selling and Administrative Expense (SG&A) SG&A expense of $51.7 million met guidance and was consistent with the last quarter. As a percentage of revenue, SG&A sequentially declined due to revenue leverage.
Non-GAAP Operating Margin Non-GAAP operating margin of 5.8% met guidance, reflecting strong operational performance.
Cash Flow Cash from operations consumed approximately $16 million to support significant program ramps planned this year. Capital expenditures were $35 million, resulting in a cash outflow of approximately $51 million.
Return on Invested Capital (ROIC) ROIC of 13.2% was 420 basis points above the weighted average cost of capital, indicating strong performance to begin fiscal 2026.
Cash Cycle Cash cycle at the end of the fiscal first quarter was 69 days, 6 days higher than the last quarter, primarily due to a 6-day increase in inventory days tied to investments for anticipated revenue growth.
Revenue Growth: Plexus achieved strong year-over-year revenue growth, with revenue of $1.07 billion in Q1 2026, a 10% increase year-over-year. The company anticipates meeting or exceeding its 9%-12% revenue growth goal for fiscal 2026.
New Manufacturing Programs: Secured 22 new manufacturing programs worth $283 million in annualized revenue, including a record $220 million from the Aerospace and Defense sector.
Aerospace and Defense: Achieved record quarterly wins of $220 million in annualized revenue. Strong growth in commercial space and defense subsectors, with new disruptive technology partnerships.
Healthcare/Life Sciences: Revenue increased 10% sequentially in Q1 2026. Secured $40 million in new program wins, including next-generation imaging products.
Industrial Sector: Revenue declined 8% sequentially but is expected to grow in Q2 2026 due to demand strength in semicap and industrial equipment subsectors. Secured $23 million in new program wins.
Operational Efficiency: Focused on achieving a 6% non-GAAP operating margin for fiscal 2026. Investments in talent, technology, and facilities are ongoing to support growth and efficiency.
Cash Flow: Forecasting approximately $100 million in free cash flow for fiscal 2026 despite increased working capital investments.
Sustainability Initiatives: Partnered with TNB in Malaysia to source 100% renewable electricity for its largest global campus, significantly reducing emissions.
Global Recognition: Penang, Malaysia team recognized as one of HR Asia's Best Companies to Work For, along with awards for sustainability and tech empowerment.
Revenue Growth: The company anticipates meeting or exceeding the high end of its 9% to 12% revenue growth goal for fiscal 2026. However, this requires significant investments in working capital, which has already increased the cash cycle by 6 days.
Operating Margin: The company is targeting a 6% non-GAAP operating margin but faces headwinds from seasonal compensation cost increases, increased variable compensation expenses, and growth and efficiency investments.
Cash Flow: Despite forecasting $100 million in free cash flow for fiscal 2026, the company experienced a cash outflow of $51 million in the fiscal first quarter due to program ramp investments and capital expenditures.
Inventory Management: Inventory days increased by 6 days in the fiscal first quarter, driven by investments to support anticipated revenue growth, which could strain cash flow if not managed effectively.
Capital Expenditures: Capital spending for fiscal 2026 is now expected to be $100 million to $120 million, higher than previously estimated, which could impact free cash flow.
Aerospace and Defense Sector: Revenue growth in this sector is expected to exceed the 9% to 12% goal, but the sector faces challenges related to customer end-of-year inventory management and the need for new program ramps.
Healthcare/Life Sciences Sector: While revenue growth is expected to exceed the 9% to 12% goal, the sector faces challenges in maintaining growth momentum, with flat to low single-digit sequential growth expected in the fiscal second quarter.
Industrial Sector: The sector faces demand softness in certain subsectors, although this is offset by robust growth in the semicap and industrial equipment subsectors.
Operational Efficiency: The company is investing in operational efficiency initiatives to offset cost increases, but these investments may take time to yield significant benefits.
Revenue Growth: Plexus anticipates meeting or exceeding the high end of its 9% to 12% revenue growth goal for fiscal 2026, driven by strong market demand, program ramps, and market share gains. For Q2 2026, revenue is guided at $1.11 billion to $1.15 billion, representing 6% sequential and 15% year-over-year growth at the midpoint.
Operating Margin: The company aims to achieve a 6% non-GAAP operating margin for fiscal 2026, supported by operational efficiency initiatives and revenue growth. For Q2 2026, non-GAAP operating margin is guided at 5.6% to 6.0%.
Free Cash Flow: Despite increased investments in working capital, Plexus forecasts approximately $100 million in free cash flow for fiscal 2026.
Capital Expenditures: Capital spending for fiscal 2026 is expected to be in the range of $100 million to $120 million, slightly higher than previous estimates, to support revenue growth.
Market Sector Performance: The Aerospace and Defense sector is expected to exceed the 9% to 12% growth goal for fiscal 2026, driven by new program ramps and strong demand. The Healthcare/Life Sciences sector is also anticipated to surpass the 9% to 12% growth target, supported by program ramps and improved demand. The Industrial sector is projected to approach the 9% to 12% growth goal, with robust growth in the semicap subsector offsetting softness in other areas.
Operational Efficiency: Plexus plans to leverage operational efficiency initiatives to offset seasonal cost increases and support margin expansion.
Share Repurchase Program: For the fiscal first quarter, we acquired approximately 153,000 shares of our stock for $22.4 million. At the end of the quarter, we had approximately $63 million remaining on the current repurchase authorization.
The earnings call highlights strong financial performance, with robust growth in key sectors and optimistic guidance. New program ramps and emerging market momentum in Aerospace and Defense, alongside automation and AI initiatives, enhance operational efficiency. Despite some uncertainties in component lead times and vague management responses, the overall sentiment is positive, supported by a high ROIC and effective cash cycle management. Given the market cap, the stock is expected to react positively, likely in the 2% to 8% range.
The earnings call shows a mixed picture. While there is confidence in growth, particularly in the Healthcare and Defense sectors, there are concerns over flat revenue in key areas like Industrial and Aerospace. The Q&A reveals uncertainty in the aerospace sector and reliance on future program ramps. Despite positive guidance and strategic investments, the flat revenue and minor delays temper expectations, leading to a neutral outlook.
The earnings call reveals strong financial performance, with record cash flow and debt reduction. Despite some uncertainties, such as the Boeing contract and supply chain challenges, guidance remains optimistic with expected growth in key sectors. The new share repurchase program further boosts shareholder confidence. The company's market cap suggests moderate volatility, aligning with a positive stock price movement prediction of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.